Vitality Watch

Dossier rss preclinical 29-sep-2026
Animal model, organoid, or cell-culture result — not yet human

uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor

Key claim: A uPAR-targeting T cell engager clears senescent cells in mice and non-human primates, with serum aminotransferase activity usable as a safety monitor.

Abstract

Aging Cell, Volume 25, Issue 10, October 2026.

Why this matters

Senolytic cell therapies have been almost entirely mouse-stage; moving a uPAR-directed T-cell engager into non-human primates with a cheap, routine liver-enzyme readout for dose-finding is the kind of translational step that lets a preclinical modality start being discussed by longevity clinics and biotech watchers as ‘near-human.’ It also reinforces uPAR as the current consensus senescent-cell antigen across both BiTE and CAR-T programs. The evidence remains preclinical — the trend-vs-evidence gap is that primate data will be read in popular channels as near-clinical validation when no human efficacy or safety data exist yet.

Source

Link

Briefing card

uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
Stage: preclinical · rss · 29-sep-2026

Applies to future trial participants in immuno-senolytic programs: this preclinical package proposes routine liver enzymes as the on-treatment safety readout for dose titration.

A uPAR-targeting T cell engager clears senescent cells in mice and non-human primates, with serum aminotransferase activity usable as a safety monitor.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70742?af=R

build build 880 · 2bcef25 · 2026-11-18